Semaglutide vs Tirzepatide: Head-to-Head

Mechanism: GLP-1 vs dual GIP/GLP-1

Semaglutide is a GLP-1 receptor agonist. It binds the glucagon-like peptide-1 receptor on pancreatic beta cells (stimulating glucose-dependent insulin release), hypothalamic neurons (reducing appetite and slowing gastric emptying), and cardiac tissue (contributing to cardiovascular benefit). It does not bind the GIP receptor.

Tirzepatide is a dual GIP and GLP-1 receptor co-agonist. The glucose-dependent insulinotropic polypeptide (GIP) receptor is expressed on pancreatic beta cells, adipose tissue, and brain regions involved in energy homeostasis. Activating GIP in combination with GLP-1 appears to enhance lipid metabolism, increase insulin sensitivity, and reduce nausea relative to GLP-1 monotherapy of comparable receptor activation strength².

Direct head-to-head: SURPASS-2

SURPASS-2 enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin. Participants were randomized to tirzepatide 5, 10, or 15 mg weekly or to semaglutide 1 mg weekly (the maximum dose approved for diabetes at the time of the trial)¹. The primary endpoint was change in HbA1c at 40 weeks.

All tirzepatide doses produced greater HbA1c reduction than semaglutide. Mean HbA1c change was −2.01, −2.24, and −2.30 percentage points across tirzepatide 5/10/15 mg, versus −1.86 with semaglutide. The proportion of participants achieving HbA1c below 7.0% was 82% to 86% with tirzepatide versus 79% with semaglutide. Mean weight loss was −7.6, −9.3, and −11.2 kg with tirzepatide 5/10/15 mg versus −5.7 kg with semaglutide.

Indirect comparison in obesity (STEP-1 vs SURMOUNT-1)

Because no randomized head-to-head trial of semaglutide 2.4 mg versus tirzepatide 15 mg in obesity has been completed, comparison relies on cross-trial extrapolation. STEP-1 (semaglutide 2.4 mg) showed 14.9% mean weight loss at 68 weeks³. SURMOUNT-1 (tirzepatide 15 mg) showed 20.9% mean weight loss at 72 weeks⁴.

Indirect comparison must be interpreted cautiously: trial populations differ slightly (SURMOUNT-1 was more racially diverse, with a higher proportion of participants from underserved populations), trial duration was different by 4 weeks, and lifestyle interventions varied. A meta-analytic comparison published in JAMA Network Open in 2024 estimated the adjusted difference at 6 to 8 percentage points in favor of tirzepatide 15 mg.

Side-effect profile differences

Both medications produce gastrointestinal adverse events as the most common reason for treatment discontinuation. In SURPASS-2, GI events were similar in frequency between tirzepatide and semaglutide¹. In cross-trial comparison between SURMOUNT-1 and STEP-1, GI event rates were broadly similar at comparable weight-loss levels, although the magnitude of weight loss makes direct comparison challenging.

Specific side effects with different rates: tirzepatide appears to produce slightly more nausea during titration but less heartburn than semaglutide. Gallbladder-related events are more common with both medications than placebo, reflecting rapid weight loss as a known risk factor for cholelithiasis.

Cardiovascular outcomes

Semaglutide has demonstrated cardiovascular benefit. The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes⁵. The SELECT trial showed a 20% reduction in MACE in adults with obesity and established cardiovascular disease without diabetes⁶.

Tirzepatide has not yet completed a dedicated cardiovascular outcomes trial in obesity. SURPASS-CVOT (in adults with type 2 diabetes and established cardiovascular disease, comparing tirzepatide with dulaglutide) is ongoing. SURMOUNT-MMO is the corresponding obesity CVOT. As of 2026, tirzepatide cannot claim formal cardiovascular benefit, though its mechanism and shared GLP-1 activation make CV benefit biologically plausible.

Cost and access considerations

Brand-name pricing for both medications in the United States exceeds $1,000 per month before insurance coverage. Insurance coverage for obesity-indicated use (Wegovy, Zepbound) is variable; coverage for type 2 diabetes is typically broader (Ozempic, Mounjaro).

Compounded versions of both medications are available from state-licensed 503A pharmacies for cash-pay patients; they are not FDA-approved. As of April 2026, FDA guidance allows compounding under standard exemptions when commercial supply is consistent and when compounding meets quality standards. Compounded pricing through telehealth providers typically ranges from $119 to $400 per month depending on dose, plan, and provider quality.

Which to choose: clinical decision factors

Patients with type 2 diabetes and high HbA1c may prioritize tirzepatide given its slightly greater glycemic efficacy. Patients with established cardiovascular disease without diabetes may prioritize semaglutide given the SELECT outcomes evidence. Patients whose primary goal is the maximum possible weight loss should consider tirzepatide. Patients who develop intolerable side effects on one molecule frequently tolerate the other.

Many clinicians take a patient-individualized approach: starting with the medication with the better insurance coverage or lower cash cost, escalating dose to maximum tolerated, and switching to the alternative if response is inadequate or side effects intolerable. Switching protocols typically involve discontinuing one medication for 1 to 2 weeks before starting the other to allow washout.

Related editorial coverage

• STEP-1 trial: semaglutide for obesity
• SURMOUNT-1 trial: tirzepatide for obesity
• Semaglutide peptide profile
• Tirzepatide peptide profile

Frequently asked questions

Is tirzepatide stronger than semaglutide?

In direct head-to-head comparison (SURPASS-2, T2D patients), tirzepatide produced greater HbA1c reduction and weight loss than semaglutide 1 mg. Indirect comparison of obesity trials suggests tirzepatide 15 mg produces about 6 percentage points more weight loss than semaglutide 2.4 mg, but no randomized head-to-head obesity trial has been completed¹⁰⁴.

Can you switch from semaglutide to tirzepatide?

Yes. Many patients switch between the two medications based on response, tolerability, or cost. Switching protocols typically involve a 1- to 2-week washout before starting the new medication. Dose conversion is approximate: semaglutide 0.5 mg ≈ tirzepatide 2.5-5 mg; semaglutide 1.0 mg ≈ tirzepatide 5-7.5 mg; semaglutide 2.4 mg ≈ tirzepatide 10-15 mg.

Which has fewer side effects?

Gastrointestinal side effects are similar in overall frequency between the two medications in head-to-head data. Specific events differ: tirzepatide may produce slightly more nausea during titration, while semaglutide may produce more heartburn. Individual variation is substantial; the better-tolerated medication for a given patient cannot be predicted in advance.

Does tirzepatide have cardiovascular outcome data?

Not yet for obesity. SURPASS-CVOT (in T2D vs dulaglutide) and SURMOUNT-MMO (in obesity) are ongoing. Semaglutide has demonstrated cardiovascular benefit in SUSTAIN-6 (T2D) and SELECT (obesity without diabetes)⁵⁶.